Corcept Therapeutics
United States
243 articles about Corcept Therapeutics
-
Corcept Therapeutics Provides Miricorilant Clinical Development Update
12/8/2022
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced an update to its programs evaluating the proprietary selective cortisol modulator miricorilant in patients with antipsychotic-induced weight gain (AIWG) and non-alcoholic steatohepatitis (NASH).
-
Corcept Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
11/3/2022
Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, reported its results for the quarter ended September 30, 2022.
-
Corcept Therapeutics to Announce Third Quarter 2022 Financial Results, Provide Corporate Update and Host Conference Call
10/27/2022
Corcept Therapeutics Incorporated announced it will report third quarter financial results and provide a corporate update on November 3, 2022.
-
Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)
10/11/2022
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced that it has initiated DAZALS – a Phase 2 trial of its proprietary selective cortisol modulator dazucorilant in patients with amyotrophic lateral sclerosis (ALS).
-
Corcept Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
8/3/2022
Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol, reported its results for the quarter ended June 30, 2022.
-
Corcept Therapeutics to Announce Second Quarter 2022 Financial Results, Provide Corporate Update and Host Conference Call
7/27/2022
Corcept Therapeutics Incorporated announced it will report second quarter financial results and provide a corporate update on August 3, 2022.
-
Otsuka and Lunbeck report positive Phase III results in agitation in Alzheimer's, Acer's vEDS program hits Phase III and BridgeBio's primary hyperoxaluria type 1 program progresses.
-
Corcept Therapeutics Initiates Rosella – A Pivotal Phase 3 Trial in Recurrent, Platinum-Resistant Ovarian Cancer
6/29/2022
Corcept Therapeutics Incorporated announced that it has initiated ROSELLA, a pivotal Phase 3 trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer.
-
Corcept Therapeutics to Start Phase 3 Trial of Relacorilant Plus Nab-Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
6/6/2022
Corcept Therapeutics Incorporated announced that, following consultation with the U.S. Food and Drug Administration, it will start a registrational Phase 3 trial of relacorilant plus nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer.
-
Corcept Therapeutics Announces First Quarter 2022 Financial Results And Provides Corporate Update
5/5/2022
Corcept Therapeutics Incorporated, a commercial-stage company engaged in the discovery and development of medications to treat severe endocrine, metabolic, oncologic and neurological disorders by modulating the effects of the hormone cortisol, reported its results for the quarter ended March 31, 2022.
-
Corcept Therapeutics Announces Appointment of Three Senior Leaders
4/7/2022
Corcept Therapeutics Incorporated announced the appointment of three individuals to Commercial and Development leadership roles.
-
Corcept Therapeutics Completes Enrollment in Phase 2 GRATITUDE Study of Miricorilant in Patients with Antipsychotic-Induced Weight Gain
4/4/2022
Corcept Therapeutics Incorporated today announced completion of enrollment in GRATITUDE – the company’s double-blind, placebo-controlled trial of its proprietary, selective cortisol modulator miricorilant as a potential treatment for patients with weight gain caused by antipsychotic medication use.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
It's a promising day for advanced ovarian cancer research as two biopharma companies achieved positive results. Here's what you need to know about research.
-
Relacorilant Plus Nab-Paclitaxel Extends Survival in Women with Recurrent, Platinum-resistant Ovarian Cancer
3/30/2022
Corcept Therapeutics Incorporated (NASDAQ: CORT), today announced overall survival (“OS”) data from its 178-patient, randomized, controlled, Phase 2 study of relacorilant plus nab-paclitaxel in patients with recurrent, platinum-resistant ovarian cancer
-
Corcept Therapeutics to Host Ovarian Cancer Program Update on Thursday, March 31, 2022
3/1/2022
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will host an event for investors and analysts on Thursday, March 31, 2022 regarding its ovarian cancer program.
-
Corcept Therapeutics Announces Fourth Quarter and Full-Year 2021 Audited Financial Results and Provides Corporate Update
2/15/2022
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial stage company engaged in the discovery, development and sale of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2021.
-
Corcept Therapeutics to Announce Fourth Quarter and Full-year 2021 Financial Results, Provide Corporate Update and Host Conference Call
2/8/2022
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2021 financial results and provide a corporate update on February 15, 2022.
-
Corcept Therapeutics Announces Preliminary Results of Previously Announced Tender Offer
12/16/2021
Corcept Therapeutics Incorporated today announced the preliminary results of its previously announced tender offer to purchase up to 10,000,000 shares of its common stock, par value $0.001 per share.
-
Corcept Therapeutics Announces Waiver of Condition to its Tender Offer for Common Shares
12/15/2021
Corcept Therapeutics Incorporated announced an update to its offer to purchase up to 10,000,000 shares of its common stock at a price not greater than $23.75 nor less than $20.75 per share closing at one minute after 11:59 P.M., New York City time, on December 15, 2021.